The role of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in the elderly

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: To report about clinical outcome of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in elderly patients. Methods: Patients with 1-4 inoperable metastases were treated with SBRT. Dose prescription ranged from 40 to 75Gy in 3-8 fractions. SBRT was delivered using the volumetric modulated arc therapy technique with flattening filter-free photon beams. The primary end points were in-field local control (LC) and toxicity. Secondary end points were overall survival (OS) and disease-specific survival (DSS). Results: 82 patients with 111 total metastases were treated. Median age was 79 years. 64 patients (78%) had a single lesion; the remaining patients had 2-4 lesions. 16 (14.4%) lesions were localized in the abdomen, 50 (45.0%) in the liver and 45 (40.5%) in the lungs. Local response was observed for 87 lesions (78.4%) while local progression was observed in 24 lesions (21.6%). Actuarial 1-year LC was 86.8%63.3%. Actuarial 1-year OS was 93.6%62.7%. 2-year findings were 76.3%64.4% and 72.0%65.6%, respectively. Actuarial 1- and 2-year DSS results were 97.5%62.0% and 81.6%64.9%, respectively. Treatment-related Grade 2-3 toxicity was observed in five patients (4.2%); Grade 1 toxicity in seven patients (5.9%) and no toxicity was observed in 85.4% of the cases. Conclusion: SBRT is a safe and effective therapeutic option for the treatment of oligometastatic disease in the elderly with acceptable rates of LC and low treatmentrelated toxicity. Advances in knowledge: The use of SBRT for oligometastatic disease in the elderly can be considered as a valuable approach, particularly for patients with fragile status or refusing other approaches.

Original languageEnglish
Article number20150111
JournalBritish Journal of Radiology
Volume88
Issue number1053
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

Radiotherapy
Survival
Therapeutics
Neoplasm Metastasis
Intensity-Modulated Radiotherapy
Photons
Abdomen
Prescriptions
Lung
Liver

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

@article{5671f60be4bb40109809c6b8dc17fc00,
title = "The role of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in the elderly",
abstract = "Objective: To report about clinical outcome of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in elderly patients. Methods: Patients with 1-4 inoperable metastases were treated with SBRT. Dose prescription ranged from 40 to 75Gy in 3-8 fractions. SBRT was delivered using the volumetric modulated arc therapy technique with flattening filter-free photon beams. The primary end points were in-field local control (LC) and toxicity. Secondary end points were overall survival (OS) and disease-specific survival (DSS). Results: 82 patients with 111 total metastases were treated. Median age was 79 years. 64 patients (78{\%}) had a single lesion; the remaining patients had 2-4 lesions. 16 (14.4{\%}) lesions were localized in the abdomen, 50 (45.0{\%}) in the liver and 45 (40.5{\%}) in the lungs. Local response was observed for 87 lesions (78.4{\%}) while local progression was observed in 24 lesions (21.6{\%}). Actuarial 1-year LC was 86.8{\%}63.3{\%}. Actuarial 1-year OS was 93.6{\%}62.7{\%}. 2-year findings were 76.3{\%}64.4{\%} and 72.0{\%}65.6{\%}, respectively. Actuarial 1- and 2-year DSS results were 97.5{\%}62.0{\%} and 81.6{\%}64.9{\%}, respectively. Treatment-related Grade 2-3 toxicity was observed in five patients (4.2{\%}); Grade 1 toxicity in seven patients (5.9{\%}) and no toxicity was observed in 85.4{\%} of the cases. Conclusion: SBRT is a safe and effective therapeutic option for the treatment of oligometastatic disease in the elderly with acceptable rates of LC and low treatmentrelated toxicity. Advances in knowledge: The use of SBRT for oligometastatic disease in the elderly can be considered as a valuable approach, particularly for patients with fragile status or refusing other approaches.",
author = "Marta Scorsetti and Elena Clerici and Piera Navarria and Giuseppe D'Agostino and Lorenzo Piergallini and {De Rose}, Fiorenza and Annamaria Ascolese and Angelo Tozzi and Cristina Iftode and Elisa Villa and Tiziana Comito and Ciro Franzese and Pietro Mancosu and Stefano Tomatis and Luca Cozzi",
year = "2015",
month = "9",
day = "1",
doi = "10.1259/bjr.20150111",
language = "English",
volume = "88",
journal = "British Journal of Radiology",
issn = "0007-1285",
publisher = "British Institute of Radiology",
number = "1053",

}

TY - JOUR

T1 - The role of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in the elderly

AU - Scorsetti, Marta

AU - Clerici, Elena

AU - Navarria, Piera

AU - D'Agostino, Giuseppe

AU - Piergallini, Lorenzo

AU - De Rose, Fiorenza

AU - Ascolese, Annamaria

AU - Tozzi, Angelo

AU - Iftode, Cristina

AU - Villa, Elisa

AU - Comito, Tiziana

AU - Franzese, Ciro

AU - Mancosu, Pietro

AU - Tomatis, Stefano

AU - Cozzi, Luca

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Objective: To report about clinical outcome of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in elderly patients. Methods: Patients with 1-4 inoperable metastases were treated with SBRT. Dose prescription ranged from 40 to 75Gy in 3-8 fractions. SBRT was delivered using the volumetric modulated arc therapy technique with flattening filter-free photon beams. The primary end points were in-field local control (LC) and toxicity. Secondary end points were overall survival (OS) and disease-specific survival (DSS). Results: 82 patients with 111 total metastases were treated. Median age was 79 years. 64 patients (78%) had a single lesion; the remaining patients had 2-4 lesions. 16 (14.4%) lesions were localized in the abdomen, 50 (45.0%) in the liver and 45 (40.5%) in the lungs. Local response was observed for 87 lesions (78.4%) while local progression was observed in 24 lesions (21.6%). Actuarial 1-year LC was 86.8%63.3%. Actuarial 1-year OS was 93.6%62.7%. 2-year findings were 76.3%64.4% and 72.0%65.6%, respectively. Actuarial 1- and 2-year DSS results were 97.5%62.0% and 81.6%64.9%, respectively. Treatment-related Grade 2-3 toxicity was observed in five patients (4.2%); Grade 1 toxicity in seven patients (5.9%) and no toxicity was observed in 85.4% of the cases. Conclusion: SBRT is a safe and effective therapeutic option for the treatment of oligometastatic disease in the elderly with acceptable rates of LC and low treatmentrelated toxicity. Advances in knowledge: The use of SBRT for oligometastatic disease in the elderly can be considered as a valuable approach, particularly for patients with fragile status or refusing other approaches.

AB - Objective: To report about clinical outcome of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in elderly patients. Methods: Patients with 1-4 inoperable metastases were treated with SBRT. Dose prescription ranged from 40 to 75Gy in 3-8 fractions. SBRT was delivered using the volumetric modulated arc therapy technique with flattening filter-free photon beams. The primary end points were in-field local control (LC) and toxicity. Secondary end points were overall survival (OS) and disease-specific survival (DSS). Results: 82 patients with 111 total metastases were treated. Median age was 79 years. 64 patients (78%) had a single lesion; the remaining patients had 2-4 lesions. 16 (14.4%) lesions were localized in the abdomen, 50 (45.0%) in the liver and 45 (40.5%) in the lungs. Local response was observed for 87 lesions (78.4%) while local progression was observed in 24 lesions (21.6%). Actuarial 1-year LC was 86.8%63.3%. Actuarial 1-year OS was 93.6%62.7%. 2-year findings were 76.3%64.4% and 72.0%65.6%, respectively. Actuarial 1- and 2-year DSS results were 97.5%62.0% and 81.6%64.9%, respectively. Treatment-related Grade 2-3 toxicity was observed in five patients (4.2%); Grade 1 toxicity in seven patients (5.9%) and no toxicity was observed in 85.4% of the cases. Conclusion: SBRT is a safe and effective therapeutic option for the treatment of oligometastatic disease in the elderly with acceptable rates of LC and low treatmentrelated toxicity. Advances in knowledge: The use of SBRT for oligometastatic disease in the elderly can be considered as a valuable approach, particularly for patients with fragile status or refusing other approaches.

UR - http://www.scopus.com/inward/record.url?scp=84941712278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941712278&partnerID=8YFLogxK

U2 - 10.1259/bjr.20150111

DO - 10.1259/bjr.20150111

M3 - Article

C2 - 26183933

AN - SCOPUS:84941712278

VL - 88

JO - British Journal of Radiology

JF - British Journal of Radiology

SN - 0007-1285

IS - 1053

M1 - 20150111

ER -